Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are prescription medications used for conditions including obesity and type 2 diabetes, but they work differently. Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. In a 72-week head-to-head obesity trial, tirzepatide produced greater average weight loss than semaglutide, although individual results and treatment suitability vary.

Key Takeaways

• Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors.
• In the direct SURMOUNT-5 trial, tirzepatide produced greater average weight and waist-circumference reductions than semaglutide at the studied doses.
• Semaglutide has an FDA-approved cardiovascular risk-reduction indication for certain adults with cardiovascular disease and higher weight person or obesity.
• Tirzepatide has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
• Both medications can cause gastrointestinal side effects and have important warnings and contraindications.

---

Semaglutide vs Tirzepatide: At a Glance

Feature	Semaglutide	Tirzepatide
Main action	GLP-1 receptor agonist	GIP + GLP-1 receptor agonist
Common weight-management brand	Wegovy	Zepbound
Common diabetes brand	Ozempic	Mounjaro
Weight-management injection	Weekly	Weekly
Oral semaglutide products	Yes	No
FDA-approved obesity treatment	Yes	Yes
FDA-approved OSA treatment	Not the same indication	Yes, Zepbound
Cardiovascular risk-reduction indication	Wegovy has one for certain adults	Different approved indications
Common side effects	Nausea, diarrhea, vomiting, constipation	Nausea, diarrhea, vomiting, constipation
Direct head-to-head weight-loss evidence	Lower average loss in SURMOUNT-5	Greater average loss in SURMOUNT-5

The brand name matters. Wegovy and Ozempic contain semaglutide, while Zepbound and Mounjaro contain tirzepatide. Their FDA-approved uses are not identical. For example, Ozempic is primarily approved for type 2 diabetes, while Wegovy is approved for chronic weight management in specified populations.

How Semaglutide and Tirzepatide Work

Semaglutide

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone involved in appetite regulation, blood glucose control and digestion.

By activating GLP-1 receptors, semaglutide can help reduce appetite and food intake while improving blood sugar control. Wegovy is used for chronic weight management in eligible patients, while Ozempic is used for certain adults with type 2 diabetes.

Tirzepatide

Tirzepatide is different because it activates two hormone pathways: GIP and GLP-1.

This dual action affects appetite and glucose regulation. Zepbound is approved for chronic weight management and also for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is used for type 2 diabetes.

So, the simplest biological distinction is:

Semaglutide = GLP-1

Tirzepatide = GIP + GLP-1

Weight Loss: Semaglutide vs Tirzepatide

This is one of the biggest reasons people search for this comparison.

The most useful direct evidence comes from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025. Adults with obesity but without type 2 diabetes were randomly assigned to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks. The semaglutide group used 1.7 mg or 2.4 mg weekly, while the tirzepatide group used 10 mg or 15 mg weekly.

The trial found that tirzepatide produced a greater reduction in body weight and waist circumference than semaglutide.

This finding is also consistent with more recent comparative research. A 2026 systematic review and meta-analysis of 10 studies involving more than 41,000 participants found greater average percentage weight reduction with tirzepatide, although the studies varied considerably in design and population.

However, there is an important limitation.

These results do not mean every person will lose more weight with tirzepatide. Clinical-trial averages describe groups, not individual outcomes. Dose escalation, treatment duration, side effects, adherence, underlying health conditions and other factors can affect results.

There is also a newer wrinkle for semaglutide. In March 2026, the FDA approved Wegovy HD, a 7.2 mg semaglutide injection, for certain adults with obesity or overweight. The 72-week SURMOUNT-5 comparison used semaglutide doses up to 2.4 mg, so its results should not be presented as a direct comparison between tirzepatide and 7.2 mg semaglutide.

FDA-Approved Uses in the U.S.

The medications overlap, but their approved uses differ.

Semaglutide products include:

• Wegovy: chronic weight management in eligible adults and certain adolescents, plus cardiovascular risk reduction for certain adults with established cardiovascular disease and overweight or obesity. Wegovy also has an FDA-approved indication for certain adults with MASH.
• Ozempic: blood glucose control in adults with type 2 diabetes and reduction of certain cardiovascular and kidney risks in specified patients.

Tirzepatide products include:

• Zepbound: chronic weight management in eligible adults and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
• Mounjaro: treatment of type 2 diabetes.

This distinction is important because you should compare the specific product and indication, not simply the generic drug names.

Side Effects and Safety

Both medications commonly cause gastrointestinal symptoms. These can include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal discomfort or pain
• Indigestion

These effects can be particularly noticeable while the dose is being increased.

Both medications also carry important warnings, including a boxed warning concerning thyroid C-cell tumors based on findings in rodents. They are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Other serious risks and precautions can include pancreatitis, gallbladder problems, kidney injury and severe gastrointestinal reactions. The exact warnings and indications depend on the specific product.

One safety detail has also changed recently: in January 2026, the FDA said its review did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonist medications and requested removal of that warning from affected labeling.

Which Factors May Matter When Choosing Between Them?

There is no single answer that applies to everyone.

A clinician may consider:

Weight-loss goals: Current direct evidence shows greater average weight reduction with tirzepatide at the doses studied in SURMOUNT-5.

Type 2 diabetes: Both drug classes can improve glucose control, but the appropriate product depends on the patient’s diagnosis, treatment goals and other medications.

Cardiovascular disease: Wegovy has specific FDA-approved cardiovascular risk-reduction evidence in adults with established cardiovascular disease and overweight or obesity. In the SELECT trial, Wegovy reduced major cardiovascular events compared with placebo.

Obstructive sleep apnea: Zepbound has a specific FDA-approved indication for moderate-to-severe OSA in adults with obesity.

Tolerance: Gastrointestinal side effects can influence whether someone can stay on a medication long enough to benefit.

Access and cost: Insurance coverage, pharmacy availability and individual eligibility can substantially affect which treatment is practical.

The American College of Physicians’ 2026 guideline lists both semaglutide and tirzepatide among first-line pharmacologic options for appropriate adults with obesity, while emphasizing discussion of benefits, harms, costs, access, medical conditions and patient preferences.

Can You Switch From Semaglutide to Tirzepatide?

Switching may be possible, but it should be planned with a healthcare professional.

The correct timing and starting dose depend on the medication being used, the current dose, treatment response, side effects and medical history. Taking the two medications together without medical direction is not appropriate.

Do not independently stop one prescription and start another simply because a comparison chart suggests one produces more average weight loss.

Frequently Asked Questions

Is tirzepatide better than semaglutide for weight loss?

Direct evidence from SURMOUNT-5 found greater average weight loss with tirzepatide than with semaglutide at the doses studied over 72 weeks. However, that does not establish that tirzepatide is the right choice for every individual. Medical history, tolerability, approved indications, cost, access and treatment goals also matter.

Is tirzepatide a GLP-1 drug?

Tirzepatide is commonly grouped with GLP-1 medicines, but technically it is a dual GIP and GLP-1 receptor agonist. Semaglutide acts primarily through the GLP-1 receptor. This difference in mechanism is one of the main distinctions between the two medications.

Which has fewer side effects?

There is no simple winner based on side effects. Both can cause gastrointestinal problems such as nausea, diarrhea, vomiting and constipation. The frequency and severity can vary by dose, study population and individual response. A healthcare professional can help assess risks based on your medical history.

Are Wegovy and Zepbound the same medication?

No. Wegovy contains semaglutide, while Zepbound contains tirzepatide. Wegovy works through the GLP-1 pathway, while Zepbound activates both GIP and GLP-1 receptors. Both are FDA-approved for chronic weight management in eligible adults, but they have different additional indications.

Can you take semaglutide and tirzepatide together?

They should not be combined unless specifically directed by a qualified healthcare professional. Both affect incretin hormone pathways, and combining prescription medications without medical supervision can increase risks without established benefit.

Conclusion

Semaglutide vs tirzepatide is not simply a contest between two identical weight-loss drugs. Semaglutide is a GLP-1 receptor agonist, while tirzepatide targets both GIP and GLP-1 receptors.

For weight loss, the strongest direct comparison currently available found greater average weight reduction with tirzepatide at the studied doses. At the same time, semaglutide has important established FDA-approved benefits, including cardiovascular risk reduction for certain adults with cardiovascular disease and overweight or obesity. Tirzepatide has its own distinct advantage in terms of its FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

The most appropriate medication depends on the person’s diagnosis, treatment goals, medical history, tolerability, access and the specific FDA-approved product being considered. A qualified healthcare professional can use those factors to determine an appropriate treatment plan.